Cambium Networks Faces Stock Decline and Lowered Revenue Expectations

1 Mins read

Shares of Cambium Networks, a wireless-infrastructure company based in Rolling Meadows, Illinois, plummeted over 30% and reached a 52-week low following the announcement that its third-quarter revenue would fall below expectations. The news prompted several Wall Street firms to reevaluate their opinions on the stock.

At present, Cambium Networks’ shares are trading at $5.21, down 34%, and hit a low of $4.41 earlier in the session.

Yesterday, after the closing bell, Cambium revealed that it anticipates third-quarter revenue between $40 million and $45 million. This projection is significantly lower than its previous forecast of $62 million to $70 million and the $64.2 million estimated by analysts.

The company attributes the revenue shortfall to various factors, including a delay in government defense orders caused by federal budgetary timing issues. As a result, Cambium Networks has also withdrawn its full-year guidance.

Following this update, Oppenheimer analysts downgraded their rating on Cambium shares from outperform to perform and lowered their price target from $15 to an unspecified amount. In a research note, they highlighted fundamental issues within the company and expressed skepticism about its long-term growth prospects. The analysts stated that they do not foresee Cambium shares rebounding until these trends are reversed.

Additionally, JMP Securities analysts downgraded Cambium shares from market outperform to market perform, while Raymond James analysts maintained their outperform rating on the stock but decreased their price target to $12 from $15.

Related posts

GitLab Stock Surges on First Ever Adjusted Operating Profit

1 Mins read
GitLab’s stock experienced a significant surge on Tuesday following the announcement of its first ever adjusted operating profit. Despite this positive development,…

Virgin Galactic Faces Stock Decline Amid Founder's Money Decision

2 Mins read
Virgin Galactic stock experienced a sharp decline in early trading on Monday due to founder Richard Branson’s announcement that he won’t be…

EyePoint Pharmaceuticals Announces Positive Results in Phase 2 Trial for Macular Degeneration Treatment

1 Mins read
EyePoint Pharmaceuticals, a Massachusetts-based company, revealed exciting news on Monday regarding the second-phase trial of its investigational treatment for macular degeneration. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

53 + = 56